{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:38:17Z","timestamp":1747204697447,"version":"3.40.5"},"posted":{"date-parts":[[2023,6,13]]},"group-title":"In Review","reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,6,6]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Purpose<\/bold>: patients with auto-antibodies neutralizing type I interferons (anti-IFN auto-Abs) are at risk of severe forms of coronavirus disease 19 (COVID-19). The chest computed tomography (CT) scan characteristics of critically ill COVID-19 patients harboring these auto-Abs have never been reported.\n<bold>Methods<\/bold>: Bicentric ancillary study of the ANTICOV study (observational prospective cohort of severe COVID-19 patients admitted to the intensive care unit (ICU) for hypoxemic acute respiratory failure) on chest CT scan characteristics (severity score, parenchymal, pleural, vascular patterns). Anti-IFN auto-Abs were detected using a luciferase neutralization reporting assay. Imaging data were collected through independent blinded reading of two thoracic radiologists of chest CT studies performed at ICU admission (\u00b172h). The primary outcome measure was the evaluation of severity by the total severity score (TSS) and the CT severity score (CTSS) according to the presence or absence of anti-IFN auto-Abs.\n<bold>Results<\/bold>: 231 critically ill COVID-19 patients were included in the study (mean age 59.5\u00b112.7 years; males 74.6%). Day 90 mortality was 29.5% (n=72\/244). There was a trend towards more severe radiological lesions in patients with auto-IFN anti-Abs than in others, not reaching statistical significance (median CTSS 27.5 (21.0-34.8] versus 24.0 (19.0-30.0), p=0.052; median TSS 14.5 (10.2-17.0) versus 12.0 (9.0-15.0), p=0.070). The extra-parenchymal evaluation found no difference in the proportion of patients with pleural effusion, mediastinal lymphadenopathy or thymal abnormalities in the two populations. The prevalence of pulmonary embolism was not significantly different between groups (8.7% versus 5.3%, p=0.623, n=175).\n<bold>Conclusion<\/bold>: There was no significant difference in disease severity as evaluated by chest CT in severe COVID-19 patients admitted to the ICU for hypoxemic acute respiratory failure with or without anti-IFN auto-Abs.<\/p>","DOI":"10.21203\/rs.3.rs-3029654\/v1","type":"posted-content","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T20:50:26Z","timestamp":1686689426000},"source":"Crossref","is-referenced-by-count":1,"title":["Chest computed tomography characteristics of critically ill COVID-19 patients with auto-antibodies against type I interferons"],"prefix":"10.21203","author":[{"given":"Baptiste Lafont","family":"Rapnouil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Zaarour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Arrestier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastien","family":"Peiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Moncomble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lodie","family":"Parfait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Bella\u00efche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand","family":"Mekontso-Dessap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Mule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4320","authenticated-orcid":false,"given":"Nicolas","family":"de Prost","sequence":"additional","affiliation":[{"name":"H\u00f4pital Henri Mondor: Hopital Henri Mondor"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00134-020-06294-x","article-title":"Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study","volume":"47","author":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators","year":"2021","unstructured":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47:60\u201373. https:\/\/doi.org\/10.1007\/s00134-020-06294-x.","journal-title":"Intensive Care Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang Q","year":"2020","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. https:\/\/doi.org\/10.1126\/science.abd4570.","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in ~ 1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano T","year":"2021","unstructured":"Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, et al. X-linked recessive TLR7 deficiency in ~ 1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6:eabl4348. https:\/\/doi.org\/10.1126\/sciimmunol.abl4348.","journal-title":"Sci Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard P","year":"2020","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. https:\/\/doi.org\/10.1126\/science.abd4585.","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths 2022","author":"Bastard P","unstructured":"Bastard P, Gervais A, Voyer TL, Rosain J, Philippot Q, Manry J et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths 2022:64. https:\/\/doi.org\/10.1126\/sciimmunol.abl4340."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e2200413119","DOI":"10.1073\/pnas.2200413119","article-title":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies","volume":"119","author":"Manry J","year":"2022","unstructured":"Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci USA. 2022;119:e2200413119. https:\/\/doi.org\/10.1073\/pnas.2200413119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijid.2023.03.011","article-title":"Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis","volume":"130","author":"Wang X","year":"2023","unstructured":"Wang X, Tang Q, Li H, Jiang H, Xu J, Bergquist R, et al. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis. Int J Infect Dis. 2023;130:147\u201352. https:\/\/doi.org\/10.1016\/j.ijid.2023.03.011.","journal-title":"Int J Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13613-022-01095-5","article-title":"Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study","volume":"12","author":"Arrestier R","year":"2022","unstructured":"Arrestier R, Bastard P, Belmondo T, Voiriot G, Urbina T, Luyt C-E, et al. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study. Ann Intensive Care. 2022;12:121. https:\/\/doi.org\/10.1186\/s13613-022-01095-5.","journal-title":"Ann Intensive Care"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj J","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718\u201324. https:\/\/doi.org\/10.1126\/science.abc6027.","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"eabh2624","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"Wijst MGP","year":"2021","unstructured":"Van Der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624. https:\/\/doi.org\/10.1126\/scitranslmed.abh2624.","journal-title":"Sci Transl Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/thoraxjnl-2020-215383","article-title":"Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis","volume":"76","author":"Tan BK","year":"2021","unstructured":"Tan BK, Mainbourg S, Friggeri A, Bertoletti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76:970\u20139. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215383.","journal-title":"Thorax"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"E262","DOI":"10.1148\/radiol.2021204522","article-title":"COVID-19 Imaging: What We Know Now and What Remains Unknown","volume":"299","author":"Kanne JP","year":"2021","unstructured":"Kanne JP, Bai H, Bernheim A, Chung M, Haramati LB, Kallmes DF, et al. COVID-19 Imaging: What We Know Now and What Remains Unknown. Radiology. 2021;299:E262\u201379. https:\/\/doi.org\/10.1148\/radiol.2021204522.","journal-title":"Radiology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall JC","year":"2020","unstructured":"Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7.","journal-title":"Lancet Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent JL","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310. https:\/\/doi.org\/10.1007\/BF01709751.","journal-title":"Intensive Care Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1007\/s00330-020-06817-6","article-title":"CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)","volume":"30","author":"Li K","year":"2020","unstructured":"Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020;30:4407\u201316. https:\/\/doi.org\/10.1007\/s00330-020-06817-6.","journal-title":"Eur Radiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e200047","DOI":"10.1148\/ryct.2020200047","article-title":"Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19","volume":"2","author":"Yang R","year":"2020","unstructured":"Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19. Radiology: Cardiothorac Imaging. 2020;2:e200047. https:\/\/doi.org\/10.1148\/ryct.2020200047.","journal-title":"Radiology: Cardiothorac Imaging"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e20211387","DOI":"10.1084\/jem.20211387","article-title":"Human autoantibodies underlying infectious diseases","volume":"219","author":"Puel A","year":"2022","unstructured":"Puel A, Bastard P, Bustamante J, Casanova J-L. Human autoantibodies underlying infectious diseases. J Exp Med. 2022;219:e20211387. https:\/\/doi.org\/10.1084\/jem.20211387.","journal-title":"J Exp Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang Q","year":"2022","unstructured":"Zhang Q, Bastard P, Human Genetic COVID, Effort, Karbuz A, Gervais A, Tayoun AA, et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587\u201398. https:\/\/doi.org\/10.1038\/s41586-022-04447-0.","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1146\/annurev-immunol-101921-050835","article-title":"Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia","volume":"41","author":"Su HC","year":"2023","unstructured":"Su HC, Jing H, Zhang Y, Casanova J-L. Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. Annu Rev Immunol. 2023;41:561\u201385. https:\/\/doi.org\/10.1146\/annurev-immunol-101921-050835.","journal-title":"Annu Rev Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13073-023-01173-8","article-title":"Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19","volume":"15","author":"Matuozzo D","year":"2023","unstructured":"Matuozzo D, Talouarn E, Marchal A, Zhang P, Manry J, Seeleuthner Y, et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med. 2023;15:22. https:\/\/doi.org\/10.1186\/s13073-023-01173-8.","journal-title":"Genome Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"Osuchowski MF","year":"2021","unstructured":"Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. The Lancet Respiratory Medicine. 2021;9:622\u201342. https:\/\/doi.org\/10.1016\/S2213-2600(21)00218-6.","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1148\/radiology.189.3.8234692","article-title":"Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation","volume":"189","author":"Remy-Jardin M","year":"1993","unstructured":"Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology. 1993;189:693\u20138. https:\/\/doi.org\/10.1148\/radiology.189.3.8234692.","journal-title":"Radiology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01512-9","article-title":"Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia","author":"Philippot Q","year":"2023","unstructured":"Philippot Q, Fekkar A, Gervais A, Le Voyer T, Boers LS, Conil C, et al. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia. J Clin Immunol. 2023. https:\/\/doi.org\/10.1007\/s10875-023-01512-9.","journal-title":"J Clin Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation","volume":"131","author":"Esmon CT","year":"2005","unstructured":"Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417\u201330. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05753.x.","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"12081","DOI":"10.3390\/ijms222112081","article-title":"Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications","volume":"22","author":"Higashikuni Y","year":"2021","unstructured":"Higashikuni Y, Liu W, Obana T, Sata M. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. IJMS. 2021;22:12081. https:\/\/doi.org\/10.3390\/ijms222112081.","journal-title":"IJMS"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","article-title":"Type I interferons and SARS-CoV-2: from cells to organisms","volume":"74","author":"Bastard P","year":"2022","unstructured":"Bastard P, Zhang Q, Zhang S-Y, Jouanguy E, Casanova J-L. Type I interferons and SARS-CoV-2: from cells to organisms. Curr Opin Immunol. 2022;74:172\u201382. https:\/\/doi.org\/10.1016\/j.coi.2022.01.003.","journal-title":"Curr Opin Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx A","year":"2021","unstructured":"Marx A, Yamada Y, Simon-Keller K, Schalke B, Willcox N, Str\u00f6bel P, et al. Thymus and autoimmunity. Semin Immunopathol. 2021;43:45\u201364. https:\/\/doi.org\/10.1007\/s00281-021-00842-3.","journal-title":"Semin Immunopathol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","article-title":"Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1","volume":"3","author":"Meager A","year":"2006","unstructured":"Meager A, Visvalingam K, Peterson P, M\u00f6ll K, Murum\u00e4gi A, Krohn K, et al. Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1. PLoS Med. 2006;3:e289. https:\/\/doi.org\/10.1371\/journal.pmed.0030289.","journal-title":"PLoS Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"676236","DOI":"10.3389\/fimmu.2021.676236","article-title":"Age-Related Changes in Thymic Central Tolerance","volume":"12","author":"Srinivasan J","year":"2021","unstructured":"Srinivasan J, Lancaster JN, Singarapu N, Hale LP, Ehrlich LIR, Richie ER. Age-Related Changes in Thymic Central Tolerance. Front Immunol. 2021;12:676236. https:\/\/doi.org\/10.3389\/fimmu.2021.676236.","journal-title":"Front Immunol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3029654\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3029654\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T15:13:44Z","timestamp":1703517224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3029654\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":29,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3029654\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s10875-023-01606-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,6,13]]},"subtype":"preprint"}}